Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SECURE POINT TECHNOLOGIES INC | bform8k120522ex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 16, 2012
IMPLANT SCIENCES CORPORATION
(Exact name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)
| 001-14949 |
| 04-2837126 |
| (Commission File Number) |
| (I.R.S. Employer Identification Number) |
600 Research Drive
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices, including Zip Code)
(978) 752-1700
(Registrant’s Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02.
Results of Operations and Financial Condition
On May 16, 2012, the Company issued a press release announcing its financial results for the third quarter and nine months ended March 31, 2012.
Item 7.01.
Regulation FD Disclosure
On May 16, 2012, the Company issued a press release announcing the event described in Item 2.02 above. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference. The press release and the information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits
| (d) | Exhibits |
| Exhibit No. |
| Description |
| 99.1 |
| Press Release of Implant Sciences Corporation, dated May 16, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMPLANT SCIENCES CORPORATION |
| By: /s/ Roger P. Deschenes |
| Roger P. Deschenes |
| Vice President, Finance and Chief Financial Officer |
Date: May 22, 2012
EXHIBIT INDEX
| (d) | Exhibits |
| Exhibit No. |
| Description |
| 99.1 |
| Press Release of Implant Sciences Corporation, dated May 16, 2012. |